Edition:
United States

Key Developments: Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

139.27USD
3:33pm EDT
Change (% chg)

$-3.26 (-2.28%)
Prev Close
$142.53
Open
$141.88
Day's High
$142.30
Day's Low
$137.40
Volume
1,569,751
Avg. Vol
1,729,511
52-wk High
$208.88
52-wk Low
$124.16

Search Stocks

Latest Key Developments (Source: Significant Developments)

Alexion Pharmaceuticals Inc gives FY 2016 guidance
Wednesday, 3 Feb 2016 06:31am EST 

Alexion Pharmaceuticals Inc:Expects FY 2016 constant currency total product revenues of $3.170 to $3.220 billion.Expects FY 2016 constant currency earnings per share of $5.31 to $5.51.  Full Article

Alexion Pharmaceuticals Inc says NEJM publishes pivotal phase 3 data on Kanuma in children and adults with lysosomal acid lipase deficiency
Wednesday, 9 Sep 2015 05:00pm EDT 

Alexion Pharmaceuticals Inc:Says NEJM publishes pivotal phase 3 data on Kanuma in children and adults with lysosomal acid lipase deficiency.In the study, Kanuma met the primary endpoint of alanine aminotransferase normalization compared with placebo as well as six secondary endpoints.  Full Article

Alexion Pharmaceuticals Inc raises FY 2015 revenue guidance and lowers FY 2015 EPS guidance
Thursday, 30 Jul 2015 06:30am EDT 

Alexion Pharmaceuticals Inc:Raises FY 2015 revenue from the previous range of $2.55 to $2.6 billion to the higher and narrower range of $2.6 to $2.62 billion.Revises FY 2015 non-GAAP EPS guidance to the range of $4.70-$4.80 per share from the previous range of $5.60 to $5.80 per share.FY 2015 revenue of $2.63 billion and EPS of $4.98 - Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals Inc's Strensiq receives marketing approval in Japan
Monday, 6 Jul 2015 06:00am EDT 

Alexion Pharmaceuticals Inc:Says Japan's Ministry of Health, Labour and Welfare approves the Co's New Drug Applicatio for the use of Strensiq as a treatment for patients in Japan with hypophosphatasia (HPP).Expects that initial patients with HPP in Japan will start commercial treatment with Strensiq by late Q3 2015.  Full Article

Alexion Pharmaceuticals completes acquisition of Synageva
Tuesday, 23 Jun 2015 06:30am EDT 

Alexion Pharmaceuticals:Completed its previously announced acquisition of Synageva BioPharma Corp., strengthening its global leadership in devastating and rare diseases, and creating the most robust rare disease pipeline in the biotech industry across a range of therapeutic modalities.Transaction was completed through a merger of Synageva with and into a direct, wholly owned subsidiary of Alexion.  Full Article

Alexion Pharmaceuticals Inc will acquire Synageva BioPharma Corp
Wednesday, 6 May 2015 06:30am EDT 

Alexion Pharmaceuticals Inc and Synageva BioPharma Corp:Have entered into definitive agreement pursuant to which Alexion will acquire Synageva.Says acquisition for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5.Says acquisition strengthens Alexion's global leadership in developing and commercializing transformative therapies for patients with devastating and rare diseases.  Full Article

Alexion Pharmaceuticals Inc reaffirms FY 2015 guidance
Thursday, 23 Apr 2015 06:30am EDT 

Alexion Pharmaceuticals Inc:Reiterates FY 2015 worldwide net product sales are to be within a range of $2.55 to $2.6 billion.Reiterates FY 2015 Non-GAAP earnings per share to be $5.60 to $5.80.FY 2015 revenue of $2.6 bln - Thomson Reuters I/B/E/S.  Full Article

Alexion Pharmaceuticals Inc announces new data from first natural history study in juveniles with hypophosphatasia (hpp) showing substantial disease burden
Saturday, 7 Mar 2015 03:22pm EST 

Alexion Pharmaceuticals Inc:Announced that researchers presented new data from a retrospective, multinational natural history study of children (symptom onset ≥6 months to <18 years) with hypophosphatasia (HPP).In this study, which included 32 patients with juvenile-onset HPP, children with HPP had substantial disease burden, particularly with regard to musculoskeletal abnormalities and growth deficiencies.Children from this cohort experienced HPP-related skeletal problems, other disease complications and morbidity that persisted despite standard efforts to control symptoms.  Full Article

Alexion Pharmaceuticals Inc reaffirms FY 2015 guidance - Conference Call
Monday, 2 Mar 2015 03:30pm EST 

Alexion Pharmaceuticals Inc:Says FY 2015 financial guidance includes revenue of $2.55 billion to $2.6 billion and EPS guidance is at $5.60 to $5.80 per share.  Full Article

FDA grants priority review for Alexion Pharmaceuticals's Asfotase Alfa as a treatment for patients with Hypophosphatasia
Monday, 2 Mar 2015 06:30am EST 

Alexion Pharmaceuticals Inc:Says the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's Biologics License Application (BLA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for treatment of patients with infantile- and juvenile-onset hypophosphatasia (HPP).BLA submission is supported by data from 71 treated patients with HPP enrolled in three prospective studies and their extensions, as well as two retrospective natural history studies.  Full Article

BRIEF-Alexion says CEO David Hallal's 2015 compensation was $14.7 mln

* Says CFO Vikas Sinha FY 2015 total compensation $4.7 million versus $7 million in FY 2014 - sec filing

Search Stocks